Cancer News and Research

Latest Cancer News and Research

$FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates$

FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates

The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk. Bisphosphonates inhibit the loss of bone mass in people with osteoporosis.

14 Oct 2010

IsoRay initiates study of Cesium-131 brachytherapy seeds for NSCLC cancer

IsoRay, Inc. announced today the initiation of a multi-institutional study of Cesium-131 brachytherapy seeds (internal radiation therapy) for use in Non Small Cell Lung Cancers (NSCLC). A number of institutions and physicians will be working to collect scientific data to further the use of Cesium-131 internal radiation therapy in conjunction with surgery for NSCLC.

14 Oct 2010

Research finds fat cells can secrete hormones

Scientists are reporting new evidence that the fat tissue in those spare tires and lower belly pooches - far from being a dormant storage depot for surplus calories - is an active organ that sends chemical signals to other parts of the body, perhaps increasing the risk of heart attacks, cancer, and other diseases. They are reporting discovery of 20 new hormones and other substances not previously known to be secreted into the blood by human fat cells and verification that fat secretes dozens of hormones and other chemical messengers.

14 Oct 2010

Study finds hemostatic powder effective in treating 95% of patients with bleeding peptic ulcers

A new material similar to that used by the U.S. Military to treat traumatic injuries is showing promise as the next novel treatment for bleeding ulcers, a condition that commonly affects up to 15 per cent of adults, according to Hong Kong physician Dr. James Lau.

14 Oct 2010

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.

14 Oct 2010

Risingsun signs consent decree to stop selling unapproved drugs

The U.S. Food and Drug Administration today announced that Toby McAdam and Greta Armstrong, doing business as Risingsun Health and The Center for Complimentary and Alternative Health of Livingston, Montana, have signed a consent decree that prohibits them from manufacturing and selling unapproved new drugs and adulterated or misbranded dietary supplements in violation of the law.

14 Oct 2010

Researchers propose Nintendo Wii gaming to control gestational diabetes in women

Many women have trouble finding time to exercise in their busy lifestyles. That's especially true for pregnant women who live in northern climates such as Canada, where the weather can limit outdoor activity during winter months every year. But exercise is critical to managing gestational diabetes, a growing problem that occurs in 2 to 9 per cent of pregnancies.

14 Oct 2010

Researchers seek to end disparities in cancer, stroke care

HealthDay/U.S. News & World Report: Research has shown that there is a racial gap in breast cancer care, "with black and Hispanic women less likely to get recommended breast cancer treatments than white patients."

14 Oct 2010

NIH awards grant to Bavarian to advance early research in filoviruses

Bavarian Nordic A/S announced today that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus).

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

Mesoblast broadens cancer indications for bone marrow transplant product

Australian regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that it is broadening the oncology applications of its "off-the-shelf" cell product for expansion of haematopoietic stem cells in patients with blood cancers. Building on the recent clinical success of Mesoblast’s proprietary cell product for expansion of cord blood, the Company will now address new markets where expansion of haematopoietic stem cells can make a meaningful impact on clinical outcomes, including diseases such as multiple myeloma.

13 Oct 2010

Global project to find biological activity in sea organisms suitable for pharmaceutical products

Researchers at the Faculty of Pharmacy at the University of Helsinki are co-ordinating an extensive project which aims to find biological activity from among organisms in the sea which would be suitable for use as a basis for pharmaceutical products. Interesting compounds isolated from organisms in the sea are chemically modified to be more suitable for medical purposes.

13 Oct 2010

Humanitas Clinic treats first cancer patient using TrueBeam technology

A 54-year-old head & neck cancer patient has become the first person in Italy to be treated using a revolutionary new linear accelerator that can deliver radiotherapy twice as fast as conventional therapy machines. The Humanitas Clinic in Rozzano-Milan carried out the treatment last week, becoming only the third hospital in Europe to begin clinical treatments using TrueBeam from Varian Medical Systems.

13 Oct 2010

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has developed an innovative method for manufacturing the company's lead product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).

13 Oct 2010

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

TrovaGene, Inc. a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled "Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

13 Oct 2010

First Edition: October 13, 2010

Today's early morning highlights from major news organizations looks at the number of people denied health coverage by major insurers, arguments before the Supreme Court on the right to sue vaccine makers, concerns about the FDA's plans on reviewing medical devices and doctors moving from private practice to hospital work.

13 Oct 2010

Canadian Cancer Society announces 'Feast for the Fight' fundraising event

Torontonians along parts of Yonge Street will have the chance to feel good while enjoying a night on the town with Feast for the Fight, a new fundraising event by the Canadian Cancer Society. Like a meal paired with fine wine, Feast for the Fight matches some of Toronto's finest restaurateurs with the country's leading cancer charity, culminating in a philanthropic dining experience.

13 Oct 2010

Fourth annual luncheon benefits MD Anderson Children's Cancer Hospital

Golf great Jack Nicklaus and veteran CBS sportscaster Jim Nantz take the stage Oct. 19 at the Hilton Americas-Houston for the 2010 Houston A Conversation With a Living Legend benefiting The University of Texas MD Anderson Cancer Center. The fourth annual luncheon, featuring an exclusive onstage interview, benefits the MD Anderson Children's Cancer Hospital and already has raised more than $472,000.

13 Oct 2010

New York Stem Cell Foundation names first six NYSCF Investigators

In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.

13 Oct 2010

First Worldwide NET Cancer Awareness Day on November 10, 2010

The World NET Community announces the first Worldwide NET Cancer Awareness Day on November 10, 2010 to raise awareness about cancers called neuroendocrine tumors (NETs) and the need for timely detection and diagnosis. More than 90% of all NET patients are incorrectly diagnosed and initially treated for the wrong disease. Misdiagnoses or delayed diagnoses mean that NET patients are treated on average five to seven years for the wrong disease; often the correct diagnosis is not made until the disease has spread (metastasized).

13 Oct 2010